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Abstract 31 
Background: The recently postulated “disease spreading hypothesis” has gained much attention, 32 
especially for Parkinson’s disease (PD). The various nonmotor symptoms (NMS) in 33 
neurodegenerative diseases would be much better explained by this hypothesis than by the 34 
degeneration of disease-specific cell populations. Motor neuron disease (MND) is primarily known 35 
as a group of diseases with a selective loss of motor function. Recent evidence, however, suggests 36 
disease spreading into nonmotor brain regions also in MND. The aim of this study was to 37 
comprehensively detect NMS in patients suffering from MND. 38 
Methods: We used a self-rating questionnaire including 30 different items of gastrointestinal, 39 
autonomic, neuropsychiatric and sleep complaints (NMSQuest) which is an established tool in PD 40 
patients. 90 MND patients were included and compared to 96 controls. 41 
Results: In total, MND patients reported significantly higher NMS scores (median: 7 points) in 42 
comparison to controls (median: 4 points). Dribbling, impaired taste/smelling, impaired swallowing, 43 
weight loss, loss of interest, sad/blues, falling and insomnia were significantly more prevalent in 44 
MND patients compared to controls. Interestingly excessive sweating was more reported in the MND 45 
group. Correlation analysis revealed an increase of total NMS score with disease progression. 46 
Conclusions: NMS in MND patients seemed to increase with disease progression which would fit 47 
with the recently postulated “disease spreading hypothesis”. The total NMS score in the MND group 48 
significantly exceeded the score for the control group, but only 8 of the 30 single complaints of the 49 
NMSQuest were significantly more often reported by MND patients. Dribbling, impaired 50 
swallowing, weight loss and falling could primarily be connected to motor neuron degeneration and 51 
declared as motor symptoms in MND. 52 
  53 
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1. Introduction 54 
Motor neuron diseases (MND), such as amyotrophic lateral sclerosis, are neurodegenerative diseases 55 
with a progressive degeneration of motor neurons and their axons. Consecutive loss of motor 56 
function like paralysis of extremities and impairment of the respiratory apparatus are the cardinal 57 
symptoms. For many neurodegenerative diseases it is well known that the pathology is not limited to 58 
the initially affected cell populations. Instead, disease spreading and involvement of other nonmotor 59 
regions in the brain seems to occur [1]. Corresponding nonmotor symptoms (NMS) like 60 
gastrointestinal-, autonomic-, neuropsychiatric- and sleep disorders are well known in these diseases. 61 
Treatments of such NMS are fundamental elements in a modern and comprehensive healthcare for 62 
patients suffering from neurodegenerative diseases [2, 3].  63 
Frequently reported comorbidity with frontotemporal dementia (FTD), autonomic dysfunctions like 64 
delayed gastric emptying and colonic transit times, small-fiber neuropathy, pain as well as 65 
abnormalities in extra-motor areas in functional brain imaging studies make it justified to classify 66 
also MND as multisystem disorders [4-10]. Moreover, recent neuropathology studies showed disease 67 
spreading also in MND and FTD, suggesting the involvement of nonmotor regions in the 68 
pathophysiology of these disorders [11-13]. 69 
The aim of this study was to investigate the appearance of NMS in MND by comparing their 70 
prevalence to age and sex matched healthy individuals using the NMS questionnaire (NMSQuest). 71 
Although the NMSQuest was designed and validated for Parkinson’s disease (PD) [2], this 72 
questionnaire with its 30 items represents a suitable screening tool for NMS in MND. 73 
74 
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2. Patients and Methods 75 
2.1. Patients 76 
Patients with definite, probable or possible amyotrophic lateral sclerosis, according to the revised El 77 
Escorial criteria [14, 15], as well as patients with primary lateral sclerosis, were recruited from 2012 78 
to 2015 at the Department of Neurology of the University Hospital Dresden. Patients suffering from 79 
genetic variants of spinal muscular atrophy, spinal bulbar muscular atrophy and FTD overlap 80 
syndromes were not included. Additionally, age and sex matched controls were recruited from 81 
several centers (Europe, USA, Japan) who participated in the NMSQuest study [3]. The study was 82 
approved by the institutional review board at the Technische Universität Dresden (EK 393122012, 83 
EK 49022016). The initial ethical approval was obtained by the research ethics committee at the 84 
University Hospital Lewisham and subsequently all involved centers obtained site-specific ethical 85 
approvals. 86 
 87 
2.2. Assessments 88 
The NMS questionnaire (NMSQuest) is a 30 item self-completed questionnaire featuring responses 89 
as “yes” and “no” to each item and was originally designed and validated for PD patients [2, 3, 16]. 90 
These 30 items can be grouped into 9 domains (digestive, urinary, memory, perceptions, mood, sex, 91 
cardiovascular, sleep and miscellaneous), as previously described [2, 3]. ‘Total NMS score’ was 92 
defined by the calculated sum of all positive (“yes”) answers of the 30 items. We additionally 93 
recorded age, gender, current symptoms with a special focus on bulbar symptoms, MND subtype, 94 
vital capacity, body weight, disease duration and the revised ALS-Functional-Rating-Scale 95 
(ALSFRS-R). A sub-cohort was retested after a period of 6 ± 3 months. 96 
 97 
2.3. Statistical analysis 98 
As the samples were not normally distributed, statistical comparisons of data between groups were 99 
made using the non-parametric Mann-Whitney U-Test (MWU) for total NMS score, NMS domains 100 
and age. The chi-squared test (χ2) was carried out for a comparison of the proportion of “yes” and 101 
“no” responses between patients and controls for each single item. Spearman rank correlation 102 
coefficients were used to examine correlations between total NMS score and demographic as well as 103 
clinical data in the MND group with a correlation coefficient of rho<0.3 considered as a weak, 104 
rho=0.3-0.59 a moderate and rho≥0.6 a strong correlation. Data were analyzed using the software 105 
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programs SPSS 21.0 (SPSS Inc., Chicago, IL) and Statistica 12.0 (StatSoft (Europe) GmbH, 106 
Hamburg, Germany). If not mentioned otherwise, all data are displayed as means ± standard 107 
deviation. Significance level was set at p<0.05. Correction for multiple testing was not applied as the 108 
study was merely exploratory and a previous hypothesis was not proposed. 109 
 110 
3. Results 111 
NMSQuest data from 90 MND patients and 96 controls were analyzed and compared. Demographic 112 
and clinical characteristics of the NMS study populations are shown in Table 1. The two groups did 113 
not differ significantly in age (MWU p=0.87) or gender (χ2 p=0.78). 114 
MND patients reported significantly more NMS in total compared to healthy individuals (Figure 1A). 115 
The sum of NMS ranged from 1 to 18 with median 7 for MND patients and from 0 to 19 in the 116 
control group with median 4 (MWU p<0.0001).  117 
Comparisons on the NMS domain level showed significantly higher scores for MND patients in the 118 
domains “digestive” (MND: 1.98 ± 1.54; control: 0.97 ± 1.26; MWU p<0.00001), “mood” (MND: 119 
0.70 ± 0.79; control: 0.42 ± 0.71; MWU p<0.01) and “cardiovascular” (MND: 0.61 ± 0.67; control: 120 
0.28 ± 0.56; MWU p<0.001). 121 
On the single item level, MND patients reported significantly more dribbling, impaired 122 
taste/smelling, impaired swallowing, weight loss, loss of interest, sad/blues, falling and insomnia. 123 
Excessive sweating was 11% more often reported in the MND group compared to the control group. 124 
The items pain and remembering were significantly less reported by MND patients. Detailed 125 
statistics are presented in Table 2 and Figure 1B. 126 
Since some of the above mentioned NMS (swallowing, dribbling and taste/smelling) could be due to 127 
bulbar paresis, we separately analyzed these items in MND patients without bulbar symptoms 128 
(MNDwbs). By doing so, there were no longer any significant difference to controls regarding 129 
dribbling (MNDwbs: 6.7%; control: 7.3%; χ2 p=0.9) and impaired taste/smelling (MNDwbs: 16.7%, 130 
control: 7.3%; χ2 p=0.12). However, significantly more patients in the “MNDwbs” group complained 131 
about impaired swallowing as compared to the control group  (MNDwbs: 26.7%; control: 10.4%; χ2 132 
p=0.02). 133 
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Correlation analysis of total NMS score to clinical and demographic data revealed a moderate 134 
correlation with ALS-FRS-R (rho = -0.42, p=0.00005) (Figure 1C), and a weak correlation with age 135 
(rho = 0.24, p=0.03) and vital capacity (rho = -0.27, p=0.02). 136 
Follow up data after 6 ± 3 months of 43 MND patients showed an increase of total NMS score (0.95 137 
± 2.64). The increase of total NMS score correlated with the decrease of ALS-FRS-R (rho = 0.34, 138 
p=0.03) and the decrease of vital capacity (rho = 0.39, p=0.03).  139 
 140 
4. Discussion and Conclusions 141 
NMS are very common in PD and other neurodegenerative disorders [2, 3, 17]. Frontotemporal 142 
impairment and memory loss are commonly known as “nonmotor” involvements in MND patients. 143 
Besides that, multiple other extra motor symptoms in MND have been reported in the last years [18], 144 
for example autonomic dysfunctions [4, 19-21], sensory symptoms due to distal small-fiber 145 
neuropathy [5] and pain [6-8]. However, this is the first pilot study for a comprehensive detection of 146 
NMS in MND patients. 147 
Dribbling, impaired taste/smelling, impaired swallowing, weight loss, loss of interest, sad/blues, 148 
falling, excessive sweating and insomnia were found to be prominent complaints in MND patients 149 
compared to controls. Dribbling, impaired swallowing, weight loss and falling could be primarily 150 
discussed as motor symptoms. In line with that, dribbling was reported with equal frequency by 151 
MND patients without bulbar symptoms compared to controls in the current study. Investigations in 152 
salivary gland function revealed saliva flow rate alterations, but these abnormalities were mild in 153 
contrast to the relevant problem of dribbling in MND patients suggesting that this symptom primarily 154 
is a consequence of bulbar motor impairment [20]. Nevertheless, swallowing was still reported 155 
significantly more often by MND patients without clinically detectable bulbar symptoms. 156 
Presumably, subjective impairment of the swallowing act exists in some patients before bulbar 157 
symptoms are observed in clinical examination.  158 
Taste/smelling complaints were significantly more reported, however only in patients suffering from 159 
bulbar symptoms. Hyposmia and hyperechogenic substantia nigra are well known predictive markers 160 
for PD [22]. Interestingly, hyperechogenicity of the substantia nigra was recently reported also in 161 
MND [23, 24]. Thus, future studies regarding hyposmia in MND are of interest for interpreting 162 
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possible similarities to PD. To our knowledge, large case-control studies with diagnostic tests for 163 
hyposmia in MND have not been previously reported.  164 
Insomnia could be regarded as NMS, but could partly be due to insufficient respiratory function 165 
during sleep and could therefore be discussed as a motor symptom. As confirmed by our results, 166 
affection of mood is a well known problem in the treatment of MND patients [25-27]. Moreover, we 167 
found excessive sweating increased in the patients as compared to the controls. This fits to recent 168 
data showing abnormal sympathetic activity with hyperhidrosis in early MND and a reduction in 169 
sweat production with disease progression [28]. Pain was significantly less reported in our study. 170 
Detailed and specific pain questionnaires already revealed the relevant impact of pain in MND [6-8], 171 
but pain in these patients is mostly a result of immobility, muscle atrophy as well as increased muscle 172 
tone and could be due to motor neuron degeneration. The question about pain in the NMSQuest 173 
aimed at “unexplained pain”, which could be confusing and lead to a false negative answer. 174 
Furthermore, the diversity of pain may not be answered in a single question. Thus, pain in the domain 175 
of NMS needs future investigation. The item impaired remembering was significantly less common 176 
in the MND group in our study, whereas an increased frequency of cognitive impairment has 177 
previously been shown in MND patients [29]. 178 
Previous investigations have suggested that quality of life in MND is not strongly related to the level 179 
of physical impairment and that MND patients displace their focus away from decreasing health 180 
status [30, 31]. These coping mechanisms possibly reduce the self-perception of NMS in MND 181 
patients. We therefore cannot exclude that some of the items which do not differ between the patient 182 
and control group in our study can be relevant after detailed interview. Future studies with objective 183 
measurement methods are therefore necessary. 184 
To summarize, the total amount of NMS among the MND patients exceeded the amount of such 185 
symptoms in the control group. The single item analysis revealed relevant complaints in MND 186 
patients and the total NMS score seemed to increase with disease progression. However, comparing 187 
total NMS of MND patients with the already published data of PD patients, the impact of NMS in 188 
MND (median 7) turned out to be less pronounced than in PD (median 9) [2]. On the single item 189 
level, the PD group reported more complaints in 16 different items compared to controls while for 190 
MND we only detected significant differences for 8 items. Additionally, the most prominent items 191 
dribbling, impaired swallowing, weight loss and falling are primarily caused by degeneration of the 192 
motor neurons. Nevertheless, NMS seem to increase with disease progression which would fit with 193 
recently published neuropathological data, suggesting spreading of disease with widespread 194 
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neuropathology at advanced stages [11-13]. Therefore, it would be of great interest to perform 195 
another study on the frequency of NMS in a group of patients representing advanced MND disease 196 
stages. Finally, we strongly believe that assessment and treatment of NMS should be included in a 197 
modern and comprehensive healthcare of MND patients.  198 
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Figure captions: 349 
Figure 1 Comparison of total NMS score (A) and single items (B) of the NMSQuest between 350 
controls (white) and MND patients (black) depicted as box plot and histograms, respectively. 351 
Correlation of total NMS score and ALSFRS-R is shown as scatterplot (C). Spearman rank 352 
correlation coefficient (rho), * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001, # p<0.06 (trend) 353 
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Table captions: 356 
Table 1 Demographic and clinical characteristics of the study populations 357 
 control group MND group 
Total number 96 90 
Ratio of female in % 52.1 50.0 
Age in yr 65.3 ± 10.5 65.1 ± 10.5 
Disease duration in yr - 3 ± 2.3 
ALS-FRS-R (Range) - 30 (8 - 46) 
Subtypes (n) - spinal onset (53)  
bulbar onset (26) 
primary lateral sclerosis (11) 
Bulbar symptoms in % - 66.7 
 358 
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Table 2 Comparison of responses between controls and MND patients  361 
 Distribution of response “yes” in percentages Chi-squared-test 
 control group MND group for yes - no 
Dribbling 7.3 41.1 0.00000 
Taste/smelling 7.3 21.1 0.0066 
Swallowing 10.4 65.6 0.00000 
Vomiting 15.6 10.0 0.25 
Constipation 26.0 25.6 0.94 
Bowel incontinence 9.4 7.8 0.69 
Bowel emptying 20.8 26.7 0.35 
Urgency 45.8 51.1 0.47 
Nocturia 60.4 50.0 0.15 
Pains 30.2 17.8 0.048 
Weight loss 6.3 21.1 0.003 
Remembering 33.3 13.3 0.001 
Loss of interest 12.5 26.7 0.015 
Hallucinations 2.1 0.0 n.c. 
Concentration 18.8 23.3 0.44 
Sad, blues 26.0 46.7 0.003 
Anxiety 15.6 23.3 0.18 
Sex drive 24.0 23.3 0.92 
Sex difficulty 16.7 24.4 0.19 
Dizzy 20.8 18.9 0.74 
Falling 7.3 42.2 0.00000 
Daytime sleepiness 9.4 10.0 0.86 
Insomnia 31.3 48.9 0.014 
Intense vivid dreams 8.3 12.2 0.38 
Acting out during dreams 10.4 6.7 0.36 
Restless legs 28.1 30.0 0.77 
Swelling 27.1 27.8 0.92 
Excessive Sweating 13.5 24.4 0.057 
Diplopia 4.2 0.0 n.c. 
Delusions 2.1 0.0 n.c. 
 362 
n.c. non-calculable 363 
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